Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial

Authors: Kevin J. Harrington, Robert L. Ferris, George R. Blumenschein, A. Dimitrios Colevas, Jérôme Fayette, Lisa Licitra, Stefan Kasper, Caroline Even, Everett E. Vokes, Francis P. Worden, Nabil F. Saba, Naomi Kiyota, Robert I. Haddad, Makoto Tahara, Viktor Grünwald, James W. Shaw, Manish Monga, Mark Lynch, Fiona Taylor, Michael DeRosa, L Morrissey, Kim Cocks, Maura L. Gillison, J. Guigay - The Lancet 2017 cited by 430